<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Article Tag Suite 1.1//EN"
  "https://jats.nlm.nih.gov/publishing/1.1/JATS-journalpublishing1.dtd">
<article xmlns:xlink="http://www.w3.org/1999/xlink"
         xmlns:mml="http://www.w3.org/1998/Math/MathML"
         article-type="research-article"
         xml:lang="en">
  <front>
    <journal-meta>
      <journal-title-group>
        <journal-title>American Journal of PharmTech Research</journal-title>
        <abbrev-journal-title abbrev-type="publisher">AJPTR</abbrev-journal-title>
      </journal-title-group>
      <issn pub-type="epub">2249-3387</issn>
      <publisher>
        <publisher-name>undefined</publisher-name>
      </publisher>
    </journal-meta>
    <article-meta>
      <article-id pub-id-type="publisher-id">AJPTR36053</article-id>
      <title-group>
        <article-title>Formulation and Evaluation of Mouth Dissolving Tablet of Propranolol HCl Using Different Superdisintegrant</article-title>
      </title-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name>
            <surname>Singh</surname>
            <given-names>Vijay Kumar</given-names>
          </name>
          <xref ref-type="aff" rid="aff1"/>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Singh</surname>
            <given-names>Utkarsh</given-names>
          </name>
          <xref ref-type="aff" rid="aff1"/>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Raj</surname>
            <given-names>Tirth</given-names>
          </name>
          <xref ref-type="aff" rid="aff1"/>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Maurya</surname>
            <given-names>Jaynt Kumar</given-names>
          </name>
          <xref ref-type="aff" rid="aff1"/>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Choudhary</surname>
            <given-names>Nishant</given-names>
          </name>
          <xref ref-type="aff" rid="aff2"/>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Chauhan</surname>
            <given-names>Hridesh Singh</given-names>
          </name>
          <xref ref-type="aff" rid="aff1"/>
        </contrib>
      </contrib-group>
      <aff id="aff1">Kamla Nehru Institute of Management and Technology, Sultanpur, India.</aff>
      <aff id="aff2">K.I.E.T School of Pharmacy, Ghaziabad, India</aff>
      <pub-date pub-type="epub" iso-8601-date="2013-12-01">
        <month>12</month>
        <day>01</day>
        <year>2013</year>
      </pub-date>
      <volume>3</volume>
      <issue>6</issue>
      <abstract>
        <p>Oral drug delivery has been known for decades as the most widely utilized route of administration among all the routes. United State Food and Drug Administration (FDA) defined ODT as “a solid dosage form containing medicinal substance or active ingredients which disintegrate rapidly usually within a matter of second when placed upon the tongue. Propranolol is a nonselective beta-adrenergic blocker and is almost completely absorbed following oral administration. However , most of drug is undergoes high first-pass metabolism by the liver and on average, only about 25% of propranolol reaches the systemic circulation. The present study investigated to development of novel fast dissolving tablet of Propranolol HCL which was by first pass metabolism, provide rapid onset of action and increasing the bioavailability of the drug. The fast dissolving tablets were prepared by Direct compression method by using different superdisintegrant like Crosspovidone, crosscarmellose sodium, sodium starch glycolate etc. The advantage of this formulation is such that in case of hypertension attack patient can take the drug without the usage of water. Therefore the main objective of the present work is to develop orodispersible tablets of Propranolol hydrochloride to improve bioavailability, disintegration time, dissolution efficacy and patient compliance.</p>
      </abstract>
      <kwd-group kwd-group-type="author">
        <kwd>Superdisintegrants</kwd>
        <kwd>Orodispersible tablets</kwd>
        <kwd>Disintegration time</kwd>
        <kwd>Direct compression</kwd>
        <kwd>Propranolol hydrochloride</kwd>
      </kwd-group>
    </article-meta>
  </front>
  <body>
    <!-- Full article body not available in metadata-only JATS export. See PDF/HTML galley. -->
  </body>
  <back/>
</article>
